The Latest Updates from CNSide Diagnostics
CNSide at Best of ASCO Austin: Free CME for Healthcare Professionals
CNSide is excited to exhibit at the Best of ASCO Austin event, where healthcare professionals can connect, learn, and explore advances in oncology education and diagnostics. This free CME opportunity is a valuable chance to stay current on clinical insights while...
CNSide to Attend AACR Special Conference on Brain Cancer Research in 2026
Connecting with the Neuro-Oncology Community at AACR’s Brain Cancer Research Conference CNSide Diagnostics is looking forward to attending the upcoming AACR Special Conference in Cancer Research: Brain Cancer in Philadelphia. Hosted by the American Association for...
CNSide’s Expert Team Behind Advanced CSF Testing
Recognizing the Experts Driving Innovation in Leptomeningeal Metastases Diagnostics On Employee Appreciation Day, we want to recognize and thank the incredible CNSide® team members whose dedication, expertise, and hard work continue to support the commercialization...
International Day of Women and Girls in Science 2026
Honoring Scientific Leaders in Cancer Diagnostics and Leptomeningeal Metastases Innovation On International Day of Women and Girls in Science, we are proud to recognize the exceptional women across the CNSide® Diagnostics and Plus Therapeutics teams who are helping...
CNSide at the NCCN Breast Cancer Conference
CNSide Diagnostics recently attended the NCCN 2026 Breast Cancer Conference hosted by the National Comprehensive Cancer Network to connect with clinicians, researchers, and oncology professionals focused on advancing breast cancer care. During the event, the CNSide...
CNSide Supports World Cancer Day: Advancing Awareness and Equity in Cancer Care
Each year on World Cancer Day, the global oncology community comes together to raise awareness, support patients, and advocate for more equitable access to cancer care. CNSide Diagnostics is proud to stand alongside clinicians, researchers, patient advocates, and...
CNSide Diagnostics to Participate in the Inaugural Brain & Spine Metastases Conference
CNSide Diagnostics is looking forward to participating in the Inaugural Brain & Spine Metastases Conference this week in Miami. The event will bring together leading clinicians, researchers, and oncology specialists focused on improving the understanding and...
Leptomeningeal Metastases: New Educational Resource for Patients and Physicians
CNSide Diagnostics and Plus Therapeutics are proud to collaborate with the Leptomeningeal Cancer Foundation to introduce a new educational resource designed to help patients, caregivers, and healthcare professionals better understand leptomeningeal metastases (LM)....
Plus Therapeutics Expands CNSide® TCE Test Availability to 48 States
New lab licenses strengthen nationwide access to CNS oncology diagnostics Plus Therapeutics (NASDAQ: PSTV) has announced a major regulatory and commercialization milestone with the expansion of laboratory licenses for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell...
Two New Strategic Executive Hires
Expanding operational and regulatory expertise to support commercialization and growth Plus Therapeutics (NASDAQ: PSTV) today announced two key leadership additions to CNSide Diagnostics, its wholly-owned subsidiary, further strengthening the company’s operational...